The prevalence of antibodies to SARS-CoV-2 among blood donors in China

Article activity feed

1. Version published to 10.1038/s41467-021-21503-x

   Mar 2, 2021
2. 

   ScreenIT

   Jul 15, 2020

   SciScore for 10.1101/2020.07.13.20153106: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	not detected.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   Serological tests: After routinely tested for transfusion-transmitted pathogens (including HIV antibody), all donation samples were tested for total antibody (TAb) against SARS-CoV-2, and the reactive samples were further tested for SARS-CoV-2 specific IgG and IgM antibodies.	HIV suggested: None SARS-CoV-2 suggested: None SARS-CoV-2 specific IgG suggested: None
   The IgM μ-chain capture method was used to detect the IgM antibodies, using the same HRP-conjugate RBD antigen.	IgM suggested: None
   Pseudotyp…

   SciScore for 10.1101/2020.07.13.20153106: (What is this?)

   Please note, not all rigor criteria are appropriate for all manuscripts.

   Table 1: Rigor

   Institutional Review Board Statement	not detected.
   Randomization	not detected.
   Blinding	not detected.
   Power Analysis	not detected.
   Sex as a biological variable	not detected.

   Table 2: Resources

   Antibodies
   Sentences	Resources
   Serological tests: After routinely tested for transfusion-transmitted pathogens (including HIV antibody), all donation samples were tested for total antibody (TAb) against SARS-CoV-2, and the reactive samples were further tested for SARS-CoV-2 specific IgG and IgM antibodies.	HIV suggested: None SARS-CoV-2 suggested: None SARS-CoV-2 specific IgG suggested: None
   The IgM μ-chain capture method was used to detect the IgM antibodies, using the same HRP-conjugate RBD antigen.	IgM suggested: None
   Pseudotype lentivirus-based neutralization test (ppNAT): For confirmation of the presence of neutralizing antibodies, all the TAb positive donation samples were tested against lentiviral pseudotyping particle (LVpp) bearing SARS-CoV-2 spike antigen.	SARS-CoV-2 spike antigen . suggested: None
   Software and Algorithms
   Sentences	Resources
   All these statistical analyses above were realized by SPSS v21.0 (IBM SPSS, Chicago, IL)	SPSS suggested: (SPSS, RRID:SCR_002865)
   Linear correlation analysis between different antibodies and ID50 was calculated by GraphPad Prism v8.0 (	GraphPad Prism suggested: (GraphPad Prism, RRID:SCR_002798)
   (GraphPad Software, San Diego, CA) or Origin 2020 (OriginLab, Northampton, MA). p<0.05 was considered statistically significant.	GraphPad suggested: (GraphPad Prism, RRID:SCR_002798)

   ---

   Results from OddPub: We did not detect open data. We also did not detect open code. Researchers are encouraged to share open data when possible (see Nature blog).

   ---

   Results from LimitationRecognizer: We detected the following sentences addressing limitations in the study:

   There are some limitations to our study that should be noted. First, the seroprevalence of our study was derived from data among healthy blood donors, which is a specific population that may have different demographic characteristics to the general population. The “healthy donor effect” should be considered, as people with mild illness or discomfort are not included.31 Second, since we didn’t follow all the 410 confirmed positive donors, and have not obtained their detailed information after donation and the nucleic acid testing results of their respiratory tract samples, we couldn’t speculate their possible exposure way and infection status. In summary, from January to April of 2020, the prevalence of antibody against SARS-CoV-2 among blood donors was 2.29% in Wuhan, 0.029% in Shenzhen, and 0.0074% in Shijiazhuang, which was highly associated with the reported COVID-19 case numbers in these cities. The earliest emergence of SARS-CoV-2 seropositivity among blood donors in Wuhan was identified on January 20, 2020, and the overall seroprevalence in this population showed a downward trend from February to April. Moreover, our study provided a prevalence-dependent antibody testing strategy for population-based serological studies, which highlighted the importance of a confirmatory neutralization test in avoiding the misleading of false-positive results of single immunoassay, in particular for a population in the non-epidemic region.

   ---

   Results from TrialIdentifier: No clinical trial numbers were referenced.

   ---

   Results from Barzooka: We did not find any issues relating to the usage of bar graphs.

   ---

   Results from JetFighter: We did not find any issues relating to colormaps.

   ---

   Results from rtransparent:

   • Thank you for including a conflict of interest statement. Authors are encouraged to include this statement when submitting to a journal.
   • Thank you for including a funding statement. Authors are encouraged to include this statement when submitting to a journal.
   • No protocol registration statement was detected.

   ---

   Read the original source
3. 

   Version published to 10.1101/2020.07.13.20153106v1 on medRxiv

   Jul 14, 2020